Voyager Therapeutics (VYGR) Return on Capital Employed (2015 - 2026)
Voyager Therapeutics (VYGR) reported Return on Capital Employed of 58.36% for Q1 2026, down 2778.0% on a YoY basis from 2.18% in Q1 2025, and down 7.89% sequentially from 54.09% in Q4 2025.
Voyager Therapeutics (VYGR) Return on Capital Employed (2015 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 12 years of Return on Capital Employed data on file, last reported at 58.36% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 2778.0% year-over-year to 58.36%; the trailing twelve-month figure through Mar 2026 stood at 58.36% (down 2778.0% YoY), and the FY2025 full-year result was 44.52%, down 1869.0% from the prior year.
- Return on Capital Employed declined to 58.36% in Q1 2026, from 54.09% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 47.21% in Q4 2023 to a low of 64.63% in Q1 2022.
- A 5-year average of 18.66% and a median of 23.15% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 7630 bps in 2022 and surged 10562 bps in 2023, its largest moves.
- Tracing VYGR's Return on Capital Employed over 5 years: stood at 51.7% in 2022, then surged by 191 bps to 47.21% in 2023, then slumped by 149 bps to 23.15% in 2024, then tumbled by 134 bps to 54.09% in 2025, then decreased by 8 bps to 58.36% in 2026.
- Business Quant data shows VYGR's Return on Capital Employed at 58.36% in Q1 2026, 54.09% in Q4 2025, and 51.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Voyager Therapeutics | 183.84 Mn | 42.36 Mn | - | -58.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.36% |
| Dec 31, 2025 | -54.09% |
| Sep 30, 2025 | -51.99% |
| Jun 30, 2025 | -41.73% |
| Mar 31, 2025 | -30.58% |
| Dec 31, 2024 | -23.15% |
| Sep 30, 2024 | 2.35% |
| Jun 30, 2024 | -1.61% |
| Mar 31, 2024 | -5.05% |
| Dec 31, 2023 | 47.21% |
| Sep 30, 2023 | 17.83% |
| Jun 30, 2023 | 31.13% |
| Mar 31, 2023 | 40.98% |
| Dec 31, 2022 | -51.70% |
| Sep 30, 2022 | -18.32% |
| Jun 30, 2022 | -55.47% |
| Mar 31, 2022 | -64.63% |
| Dec 31, 2021 | -53.22% |
| Sep 30, 2021 | -60.60% |
| Jun 30, 2021 | 3.34% |